Outbreak

Viral replication

Viral load

Pathology

Virology

Enzyme

Virus

Protease

Coronavirus

Disease

Antiviral drug

Drug

Protease inhibitor (pharmacology)

Antiretroviral therapy

2019-20 coronavirus outbreak

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Coronavirus disease 2019 (COVID-19)

Infectious disease (medical specialty)

Biochemistry

Bioinformatics

Medicine

Drug discovery

Biology

Pharmacology

Science

Promising antiviral protease inhibitors With no vaccine or proven effective drug against the virus that causes coronavirus disease 2019 (COVID-19), scientists are racing to find clinical antiviral treatments. A promising drug target is the viral main protease M pro , which plays a key role in viral replication and transcription. Dai et al. designed two inhibitors, 11a and 11b, based on analyzing the structure of the M pro active site. Both strongly inhibited the activity of M pro and showed good antiviral activity in cell culture. Compound 11a had better pharmacokinetic properties and low toxicity when tested in mice and dogs, suggesting that this compound is a promising drug candidate. Science , this issue p. 1331

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease